<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000463</url>
  </required_header>
  <id_info>
    <org_study_id>IRB20025</org_study_id>
    <nct_id>NCT05000463</nct_id>
  </id_info>
  <brief_title>Ozone Therapy in Patients With Diabetic Neuropathy</brief_title>
  <official_title>Ozone Therapy in Clinical, Psychological and Neurophysiological Pain Alleviation in Patients With Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic neuropathies are the most prevalent chronic complications of diabetes mellitus. The&#xD;
      early recognition and appropriate management of neuropathy in the patient with diabetes is&#xD;
      important for patient's quality of life and life expectancy. Ozone is well known to have&#xD;
      anti-inflammatory and analgesic effects through the inhibition of pro-inflammatory mediators;&#xD;
      as well as. stimulation of anti-inflammatory mediators' release&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:&#xD;
&#xD;
      Diabetic neuropathies are the most prevalent chronic complications of diabetes mellitus. The&#xD;
      early recognition and appropriate management of neuropathy in the patient with diabetes is&#xD;
      important for patient's quality of life and life expectancy. The clinical symptoms of DPN&#xD;
      range from pain and burning sensations (at rest or at night) to hypoesthesia, paresthesia,&#xD;
      and/or numbness . Diabetic neuropathy can be axonal or demyelinating and can affect large or&#xD;
      small neurons. Schwann cells, which are the most abundant glial cells, act as nerve axon&#xD;
      insulators and modulators of neurobiology through their role in metabolic support and injury&#xD;
      protection. In diabetic patients, church cells' function is disturbed, leading to loss of&#xD;
      glial-axon communication and nerve homeostasis, which leads to fiber loss, neurodegeneration,&#xD;
      and pain. Nerve conduction studies can detect these changes; however, there has been no&#xD;
      effective therapy for the treatment of DPN until now.&#xD;
&#xD;
      Ozone is well known to have anti-inflammatory and analgesic effects through the inhibition of&#xD;
      pro-inflammatory mediators; as well as. stimulation of anti-inflammatory mediators' release .&#xD;
      Previous studies showed that Ozone promotes peripheral vascular integrity via induction of&#xD;
      Vascular Endothelial Growth Factor (VEGF), Transforming Growth Factor Beta (TGF-β1) an&#xD;
      Platelet-Derived Growth Factor (PDGF), according with the studies of Professor Bocci that&#xD;
      demonstrated significantly increase and release of PDGF, TGF- β1 and VEGF in presence of&#xD;
      Ozone .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2021</start_date>
  <completion_date type="Anticipated">September 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Assessment</measure>
    <time_frame>6 months</time_frame>
    <description>the visual analoge scale of pain (VAS) will be assessed. No pain VAS = 1, worst pain VAS= 10</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pain, Chronic</condition>
  <arm_group>
    <arm_group_label>ozone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ozone injection under ultrasound guidance in addition to the medical treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>receive the medical treatment only. The medical treatment includes optimal glycemic control, vitamin B complex, a lipoic acid, selective serotonin reuptake inhibitors, and pregabalin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozone</intervention_name>
    <description>The participants will lay flat and the area of injection will be prepared with antiseptic. Maintenance of ultrasonography probe sterility was also guaranteed using a sterile barrier. Under sonographic guidance, superficial peroneal nerve, deep peroneal, sural , asphenous, and tibila nerves will be injected An ozone/oxygen mixture ( 25μg/ml) will be injected in each nerev</description>
    <arm_group_label>ozone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Convtrol group</intervention_name>
    <description>The medical treatment included optimal glycemic control, vitamin B complex, a lipoic acid, selective serotonin reuptake inhibitors, and pregabalin.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sixty adult diabetic patients (type II DM)&#xD;
&#xD;
          -  clinically symptomatized painful neuropathy for six or more months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with other causes of neuropathy (e.g., vitamin B12 deficiency), hereditary&#xD;
             neuropathies and entrapment neuropathies, overt neuropathy with foot ulcers and/or&#xD;
             amputation, peripheral vascular diseases, vertebral pathologies (e.g., previous&#xD;
             surgery, foraminal stenosis, spinal canal stenosis, and/or vertebral disc herniation)&#xD;
&#xD;
          -  Patients with other medical conditions such as connective tissue diseases, thyroid&#xD;
             disorders, significant renal or hepatic dysfunction, platelet dysfunction syndrome,&#xD;
             critical thrombocytopenia, hemodynamic instability and septicemia&#xD;
&#xD;
          -  local infection at the site of the procedure&#xD;
&#xD;
          -  Consistent use of nonsteroidal anti-inflammatory drugs within the last two weeks&#xD;
&#xD;
          -  Systemic corticosteroid administration or local injection at the suspected treatment&#xD;
             site within the last month&#xD;
&#xD;
          -  Recent fever or illness, hemoglobin level &lt;10 g/dL, platelet count &lt;105 _ 109/L,&#xD;
             and/or tobacco use.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emad Kamel, MD</last_name>
    <phone>+201007046058</phone>
    <email>emadzarief@aun.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emad Zarief Kamel Said</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Bocci V, Zanardi I, Travagli V. Ozone: a new therapeutic agent in vascular diseases. Am J Cardiovasc Drugs. 2011;11(2):73-82. doi: 10.2165/11539890-000000000-00000. Review.</citation>
    <PMID>21446774</PMID>
  </reference>
  <reference>
    <citation>Bril V, Tomioka S, Buchanan RA, Perkins BA; mTCNS Study Group. Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabet Med. 2009 Mar;26(3):240-6. doi: 10.1111/j.1464-5491.2009.02667.x.</citation>
    <PMID>19317818</PMID>
  </reference>
  <reference>
    <citation>Hassanien M, Elawamy A, Kamel EZ, Khalifa WA, Abolfadl GM, Roushdy ASI, El Zohne RA, Makarem YS. Perineural Platelet-Rich Plasma for Diabetic Neuropathic Pain, Could It Make a Difference? Pain Med. 2020 Apr 1;21(4):757-765. doi: 10.1093/pm/pnz140.</citation>
    <PMID>31298289</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Emad Zarief , MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

